Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Belantamab Mafodotin oder Daratumumab mit Bortezomib, Lenalidomid und Dexamethason für neu diagnostiziertes multiples Myelom (PrE1005)

11. November 2026 aktualisiert von: PrECOG, LLC.

Randomisierte Phase-3-Studie von Belantamab Mafodotin oder Daratumumab in Kombination mit Bortezomib, Lenalidomide und Dexamethason für neu diagnostiziertes multiples Myelom

Eligible participants with newly diagnosed myeloma who are not considered eligible or refuse bone marrow transplant will be enrolled. Participants will be randomized to either belantamab mafodotin or daratumumab given in combination with bortezomib, lenalidomide and dexamethasone. Treatment will continue until disease progression, unacceptable side effects or withdrawal of consent.

Belantamab mafodotin is a targeted cancer treatment that works against multiple myeloma cells. It combines a homing device (an antibody) with a powerful cell-killing drug (a toxin), delivering the toxin directly to cancer cells while largely sparing healthy cells.

Minimal residual disease (MRD) testing will be done on bone marrow samples obtained standardly during your treatment. MRD shows whether a very small number of cancer cells can still be detected after treatment, even if standard lab tests shows no signs of cancer.

The purpose of this study is to evaluate if belantamab mafodotin, bortezomib, lenalidomide and dexamethasone (BVRd) improves minimal residual disease (MRD) negative status and/or prolongs progression-free survival (PFS) compared with daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) in participants with newly diagnosed multiple myeloma.

Studienübersicht

Detaillierte Beschreibung

This proposed Phase III multicenter, study is a randomized (1:1), open-label trial designed to show belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone (VRd) will lead to higher minimal residual disease (MRD) negativity rate compared with daratumumab in combination with VRd newly diagnosed multiple myeloma (TI-NDMM). Patients must be ineligible for autologous stem cell transplantation because of their age (≥ 70 years) or aged 18 - 70 years with the presence of underlying medical conditions likely to have a negative impact on tolerability of high-dose chemotherapy with stem-cell transplantation, making them transplant ineligible OR transplant-eligible and refusing stem-cell transplantation until first relapse or later. In addition, progression-free survival (PFS) will also be longer.

After enrolling approximately 320 standard-risk patients (anticipated at approximately 400 total patients), the study will limit accrual to patients with high risk NDMM to allow for enrichment of this subgroup of patients.

Belantamab mafodotin is a monoclonal antibody that targets B-cell maturation antigen (BCMA), a protein expressed on the surface of plasma cells, and releases a cytotoxic agent called Monomethyl auristatin F, which destroys the plasma cells.

International Myeloma Working Group (IMWG) criteria will be used for disease response.

MRD samples will be obtained on standard of care bone marrow procedures. MRD testing will be performed on samples at time of screening, suspected complete response (sCR), after confirmed CR at applicable time points from Cycle1, Day 1 at 6, 12, 18 (optional), 24, 30 (optional) and 36 months then annually until progression. MRD testing will not be performed in real-time for this study. Bone marrow samples will also be obtained for future research at screening and time of progression.

Research peripheral blood samples will be obtained to measure levels of belantamab mafodotin in the blood, immune responses or antibodies to belantamab mafodotin for patients receiving belantamab mafodotin. In addition, research blood samples will be obtained on all patients to measure soluble B-cell maturation antigen (sBCMA) to help diagnose, monitor treatment effectiveness, and predict the prognosis of multiple myeloma.

Patient-reported outcomes will also be performed.

Studientyp

Interventionell

Einschreibung (Geschätzt)

500

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Iowa
      • Des Moines, Iowa, Vereinigte Staaten, 50309
        • Rekrutierung
        • Iowa Oncology Research Associates
        • Kontakt:
        • Hauptermittler:
          • Millicent Amankwah, MD
    • Maine
      • Brewer, Maine, Vereinigte Staaten, 04412
        • Rekrutierung
        • Northern Lights / Eastern Maine Medical Center
        • Kontakt:
        • Hauptermittler:
          • Sarah Sinclair, DO
    • Wisconsin

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 79 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Eligibility Criteria:

  • Patient must have suspected or confirmed newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria and must not have received more than one cycle of any myeloma treatment.

  • Patient must be considered ineligible for autologous stem cell transplantation by the treating physician because of their age (≥ 70 years) or aged 18 - 70 years with the presence of underlying medical conditions likely to have a negative impact on tolerability of high-dose chemotherapy with stem-cell transplantation, making them transplant ineligible, OR transplant-eligible and refusing stem-cell transplantation until first relapse or later.

  • Patient must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to randomization.

    • ≥ 1g/dL monoclonal protein (M-protein) on serum protein electrophoresis
    • Involved free light chain ≥ 10 mg/dL or ≥ 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (<0.26 or >1.65)
    • ≥ 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis
    • Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)
  • Patient must be ≥ 18 years and <80 years of age.

  • Patient must have an Eastern Cooperative Group (ECOG) Performance Status (PS) of 0-2 (PS 3 allowed if secondary to pain).

  • Patient must have IMWG Frailty Score <2.

  • Patient must have the ability to understand and willingness to sign a written informed consent document.

  • Patient must be willing to provide bone marrow (aspirate and/or biopsy) and blood samples for determination of International Myeloma Society (IMS) risk status and for research. Indeterminate patients with missing or unevaluable samples will be excluded.

  • Patient must have received no more than one cycle (28 days or less) of prior chemotherapy and no more than 160 mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma. Prior radiation therapy to symptomatic lesions is allowed provided there is no residual toxicity related to radiation and blood counts meet the study requirements. NOTE: Patients who have received prior treatment for smoldering multiple myeloma (SMM) are eligible.

  • Patient must have a Serum Protein Electrophoresis (SPEP), Urine Protein Electrophoresis (UPEP), and serum Free Light Chain (FLC) assay performed within 28 days prior to registration. In addition, a bone marrow biopsy and/or aspirate is required within 28 days prior to registration if measurable disease is only present in bone marrow. Otherwise, a bone marrow examination must have been performed within 90 days prior to registration.

  • Patient must have adequate organ function and marrow function as defined below, obtained ≤ 2 weeks prior to registration.

    • Absolute Neutrophil Count (ANC) ≥ 1000/microliter (mcL)
    • Platelets ˃75,000/mcL
    • Creatinine clearance (CrCl) ≥ 30 mL/min
    • Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 3x upper limit of normal (ULN)
    • Total Bilirubin ≤ 1.5x ULN or ≤ 3x ULN for patients with documented Gilbert's disease
  • Patient must agree to register to the mandatory lenalidomide (Revlimid) Risk Evaluation and Mitigation Strategy (REMS) program and be willing and able to comply with the requirements of the REMS program.

  • Patient must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.

  • Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study, and for 3 months after the last dose of protocol treatment.

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

  • Patient with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association (NYHA) Functional Classification. To be eligible for this trial, patient must be class 2 or better.

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

  • Patients must not have peripheral neuropathy ≥ Grade 2 on clinical examination or Grade 1 with pain at time of registration.

  • Patients must not have any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.

  • Patient may have a history of current or previous deep vein thrombosis (DVT) or pulmonary embolism (PE) but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation.

  • Patients must not have any known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients, or known sensitivity to mammalian-derived products.

  • Patients must not have current corneal epithelial disease except mild punctuate keratopathy.

  • Contact lenses must be avoided for participants while they are receiving belantamab mafodotin treatment unless cleared by an eye-care specialist. If cleared for use, bandaged contact lenses are specifically recommended. Contact lens use may be restarted after discontinuation of belantamab mafodotin treatment, provided the eye-care specialist confirms there are no other contraindications.

  • Patients must not have symptomatic amyloidosis or active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-proliferative disorder, skin changes) at the time of screening.

  • Patients must not receive any other concurrent chemotherapy, or any ancillary therapy considered investigational while on this protocol.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Arm A: Belantamab Mafodotin

Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone (VRd) until progression, unacceptable toxicity or participant withdrawal. 1 cycle = 28 days.

1.9 milligram/kilogram (mg/kg) intravenous (IV) will be administered every 8 weeks for first 24 weeks (Cycles 1-3), then 1.9 mg/kg every 12 weeks (Cycles 4+) until progression, unacceptable toxicity or participant withdrawal

Andere Namen:
  • Blenrep
  • GSK2857916
  • Belamaf

1.3 milligrams per square meter (mg /m²) SC on days 1, 8 and 15 of every 28 day bortezomib treatment cycle for 8 cycles

Andere Namen:
  • Velcade®

25 mg orally (PO) Days 1-21 of every 28 day lenalidomide treatment cycle.

Andere Namen:
  • Revlimid®

40 mg PO on Days 1, 8, 15, and 22 of each 28-day cycle (may decrease to 20 mg if >75 years old)

Andere Namen:
  • Dekadron
Aktiver Komparator: Arm B:

Daratumumab in combination with bortezomib, lenalidomide and dexamethasone (VRd) until progression, unacceptable toxicity or participant withdrawal. 1 cycle = 28 days.

1.3 milligrams per square meter (mg /m²) SC on days 1, 8 and 15 of every 28 day bortezomib treatment cycle for 8 cycles

Andere Namen:
  • Velcade®

25 mg orally (PO) Days 1-21 of every 28 day lenalidomide treatment cycle.

Andere Namen:
  • Revlimid®

40 mg PO on Days 1, 8, 15, and 22 of each 28-day cycle (may decrease to 20 mg if >75 years old)

Andere Namen:
  • Dekadron

1800 mg subcutaneous (SC) will be administered weekly from Week 1-8 (Cycles 1 and 2), every 2 weeks from Week 9-24 (Cycles 3-6), and every 4 weeks from Week 25 (Cycles 7+) onwards until progression, unacceptable toxicity or participant withdrawal

Andere Namen:
  • DARZALEX FASPRO™

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
MRD Negative Status
Zeitfenster: Up to 86 months

MRD negative status, defined as achieving MRD negativity at 10-5 sensitivity threshold assessed by NGS at least once during the time of confirmed CR or better response per IMWG criteria by Independent Review Committee (IRC); MRD negativity is determined by the Adaptive Biotechnologies clonoSEQ® assay result

Up to 86 months
Progression-Free Survival (PFS)
Zeitfenster: Up to 86 months

PFS, defined as the time from the date of randomization to the date of first documented disease progression per IMWG criteria by IRC or death from any cause in the absence of progression, whichever occurs first

Up to 86 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall Survival (OS)
Zeitfenster: Up to 86 months

OS, defined as the time from the date of randomization until the date of death due to any cause

Up to 86 months
Best Response of Complete Response (CR)
Zeitfenster: Up to 86 months

Defined as confirmed CR or better per IMWG criteria by IRC

Up to 86 months
Best Response of Very Good Partial Response (VGPR)
Zeitfenster: Up to 86 months

Defined as confirmed VGPR, CR or better per IMWG criteria by IRC

Up to 86 months
Overall Response Rate (ORR)
Zeitfenster: Up to 86 months

Defined as confirmed PR, VGPR, CR or better per IMWG criteria by IRC

Up to 86 months
Duration of Response (DoR)
Zeitfenster: Up to 86 months

DoR, defined as the time from first documented evidence of partial response (PR) or better until progression (PD) or death due to PD (among participants who achieve confirmed PR or better) by IRC

Up to 86 months
MRD Negative Status at 12-Month
Zeitfenster: Up to 86 months

Defined as achieving MRD negativity at 10-5 sensitivity threshold assessed by NGS in participants achieving confirmed CR or better response per IMWG criteria by Independent Review Committee (IRC) after 12 (+/-3) months; MRD negativity is determined by the Adaptive Biotechnologies clonoSEQ® assay result

Up to 86 months
Sustained MRD (sMRD) Negative Status
Zeitfenster: Up to 86 months

sMRD, defined as achieving MRD negative status at 10-5 sensitivity threshold assessed by NGS at least twice, a minimum of 1 year apart and with no MRD positive result in between, during the time of confirmed CR or better response per IMWG criteria by IRC

Up to 86 months
Adverse Events (AEs)
Zeitfenster: While on study treatment and up to 70 days after the last dose of study medication

Worst Grade 3 or Higher Treatment-Related Non-Hematologic and Overall Toxicity based on CTCAE v6.0

While on study treatment and up to 70 days after the last dose of study medication
AEs Leading to Dose Modifications
Zeitfenster: While on study treatment and up to 70 days after the last dose of study medication

AEs or Grade ≥ 2 Corneal Events Leading to Dose Modifications or Treatment Discontinuation

While on study treatment and up to 70 days after the last dose of study medication
Corneal Events
Zeitfenster: While on study treatment and up to 70 days after the last dose of study medication

Incidence of Grade ≥ 3 Corneal Events (Keratopathy Visual Acuity (KVA) scale)

While on study treatment and up to 70 days after the last dose of study medication
Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Zeitfenster: Up to 86 months

Frequency and Score of Selected PRO-CTCAE Attributes

Up to 86 months
Health-Related Quality of Life (HRQoL)
Zeitfenster: Up to 86 months

Change from Baseline in HRQoL as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20), and Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT MM) Subscale

Up to 86 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Studienstuhl: Shaji Kumar, MD, Mayo Clinic

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Dezember 2026

Primärer Abschluss (Geschätzt)

1. November 2031

Studienabschluss (Geschätzt)

1. Juni 2034

Studienanmeldedaten

Zuerst eingereicht

9. Dezember 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. Dezember 2025

Zuerst gepostet (Tatsächlich)

16. Dezember 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • PrE1005
  • GSK 300057 (Andere Kennung: GlaxoSmithKline)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Data is proprietary

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren